GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arbutus Biopharma Corp (NAS:ABUS) » Definitions » Cyclically Adjusted PB Ratio

Arbutus Biopharma (Arbutus Biopharma) Cyclically Adjusted PB Ratio : 1.05 (As of Jun. 06, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Arbutus Biopharma Cyclically Adjusted PB Ratio?

As of today (2024-06-06), Arbutus Biopharma's current share price is $3.63. Arbutus Biopharma's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $3.45. Arbutus Biopharma's Cyclically Adjusted PB Ratio for today is 1.05.

The historical rank and industry rank for Arbutus Biopharma's Cyclically Adjusted PB Ratio or its related term are showing as below:

ABUS' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.24   Med: 0.91   Max: 8.34
Current: 0.97

During the past years, Arbutus Biopharma's highest Cyclically Adjusted PB Ratio was 8.34. The lowest was 0.24. And the median was 0.91.

ABUS's Cyclically Adjusted PB Ratio is ranked better than
63.39% of 661 companies
in the Biotechnology industry
Industry Median: 1.75 vs ABUS: 0.97

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Arbutus Biopharma's adjusted book value per share data for the three months ended in Mar. 2024 was $0.636. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $3.45 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Arbutus Biopharma Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Arbutus Biopharma's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arbutus Biopharma Cyclically Adjusted PB Ratio Chart

Arbutus Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.77 1.08 1.13 0.64 0.71

Arbutus Biopharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.83 0.63 0.56 0.71 0.75

Competitive Comparison of Arbutus Biopharma's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Arbutus Biopharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arbutus Biopharma's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arbutus Biopharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Arbutus Biopharma's Cyclically Adjusted PB Ratio falls into.



Arbutus Biopharma Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Arbutus Biopharma's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=3.63/3.45
=1.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arbutus Biopharma's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Arbutus Biopharma's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.636/131.7762*131.7762
=0.636

Current CPI (Mar. 2024) = 131.7762.

Arbutus Biopharma Quarterly Data

Book Value per Share CPI Adj_Book
201406 4.762 100.560 6.240
201409 4.286 100.428 5.624
201412 3.923 99.070 5.218
201503 10.975 99.621 14.517
201506 10.837 100.684 14.184
201509 10.149 100.392 13.322
201512 10.036 99.792 13.253
201603 9.850 100.470 12.919
201606 7.871 101.688 10.200
201609 7.597 101.861 9.828
201612 3.702 101.863 4.789
201703 3.437 102.862 4.403
201706 3.195 103.349 4.074
201709 3.041 104.136 3.848
201712 2.410 104.011 3.053
201803 2.070 105.290 2.591
201806 2.056 106.317 2.548
201809 1.655 106.507 2.048
201812 1.307 105.998 1.625
201903 0.912 107.251 1.121
201906 0.566 108.070 0.690
201909 -0.893 108.329 -1.086
201912 -0.996 108.420 -1.211
202003 -0.956 108.902 -1.157
202006 -1.074 108.767 -1.301
202009 -0.571 109.815 -0.685
202012 -0.522 109.897 -0.626
202103 -0.395 111.754 -0.466
202106 -0.557 114.631 -0.640
202109 -0.277 115.734 -0.315
202112 1.169 117.630 1.310
202203 1.115 121.301 1.211
202206 1.029 125.017 1.085
202209 0.953 125.227 1.003
202212 0.869 125.222 0.914
202303 0.872 127.348 0.902
202306 0.807 128.729 0.826
202309 0.712 129.860 0.723
202312 0.624 129.419 0.635
202403 0.636 131.776 0.636

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Arbutus Biopharma  (NAS:ABUS) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Arbutus Biopharma Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Arbutus Biopharma's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Arbutus Biopharma (Arbutus Biopharma) Business Description

Traded in Other Exchanges
Address
701 Veterans Circle, Warminster, PA, USA, 18974
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.
Executives
Melissa Rewolinski director 9000 STATE ROAD, PHILADELPHIA PA 19136
Karen Sims officer: Chief Medical Officer 701 VETERANS CIRCLE, WARMINSTER PA 18974
J. Christopher Naftzger officer: General Counsel and CCO 633 LOWTHER ROAD, LEWISBERRY PA 17339
Michael J. Sofia officer: Chief Scientific Officer C/O ARBUTUS BIOPHARMA CORP., SUITE 100, 8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8
Tram Tran director C/O ARBUTUS BIOPHARMA CORPORATION, 701 VETERANS CIRCLE, WARMINSTER PA 18974
Roivant Sciences Ltd. 10 percent owner CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Michael J. Mcelhaugh officer: Chief Business Officer C/O ONCORE BIOPHARMA, INC., 3805 OLD EASTON ROAD, DOYLESTOWN PA 18902
Eric Venker director C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
James R Meyers director GILEAD SCIENCES, INC., 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Andrew Cheng director 170 HARBOR WAY, 3RD FLOOR, C/O AKERO THERAPEUTICS, INC., SOUTH SAN FRANCISCO CA 94080
Myrtle S Potter director 10 FINDERNE AVE, BRIDGEWATER NJ 08807
William H. Collier director, officer: President and CEO C/O ARBUTUS BIOPHARMA CORPORATION, 701 VETERANS CIRCLE, WARMINSTER PA 18974
Elizabeth Howard officer: Executive VP & General Counsel 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8
David C Hastings officer: Chief Financial Officer C/O ARBUTUS BIOPHARMA, 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8
Gaston Picchio officer: Chief Development Officer C/O ARBUTUS BIOPHARMA CORP, 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8

Arbutus Biopharma (Arbutus Biopharma) Headlines